Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease.

It is well established that Alzheimer's disease causing mutations in APP, PSEN1 and PSEN2 lead to a relative increased production of Abeta42, thereby fostering its deposition in plaques. Recently others and we showed that amyloid precursor protein (APP) overproduction, either as a result of genomic locus duplication or altered regulatory sequences in the APP promoter region, leads to early-onset disease. Here, we have expanded our study of genetic variability in the APP promoter to a large group of well-documented Belgian patients (n = 750, mean onset age = 75.0 +/- 8.6, range = 37-96). We identified three different APP promoter mutations (-369C-->G, -534G-->A and -479C-->T) in seven patients. In patients with onset < or =70 years (n = 204), we identified one patient carrying the London APP V717I mutation while no patients carried an APP locus duplication, indicating that APP promoter mutations (n = 2) were more frequently associated with increased risk for early-onset Alzheimer's disease. The two mutations (-369C-->G and -534G-->A) increasing APP promoter activity by nearly 2-fold and mimicking an APP duplication, appeared in probands of families with multiple patients with dementia. The -479C-->T mutation that increased APP expression only mildly (1.2-fold), was observed in four patients with onset ages ranging from 62 to 79 years (mean 71.5 years), suggesting that its contribution to disease risk is more pronounced at later age due to modulating factors. In conclusion, we provided evidence that mutations in APP regulatory sequences are more frequent than APP coding mutations, and that increased APP transcriptional activity constitutes a risk factor for Alzheimer's disease with onset ages inversely correlated with levels of APP expression.

[1]  K. Sleegers,et al.  APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. , 2006, Brain : a journal of neurology.

[2]  K. Sleegers,et al.  Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. , 2006, American journal of human genetics.

[3]  P. Deyn,et al.  Neuropsychological and behavioural correlates of CSF biomarkers in dementia , 2006, Neurochemistry International.

[4]  P. Deyn,et al.  Dose dependent effect of APOE ɛ4 on behavioral symptoms in frontal lobe dementia , 2006, Neurobiology of Aging.

[5]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[6]  C. van Broeckhoven,et al.  Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. , 2006, Neurobiology of aging.

[7]  S. Gandy,et al.  The role of cerebral amyloid β accumulation in common forms of Alzheimer disease , 2005 .

[8]  S. Gandy,et al.  The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. , 2005, The Journal of clinical investigation.

[9]  K. Sleegers,et al.  Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. , 2004, Brain : a journal of neurology.

[10]  A. Pfeffer,et al.  Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland , 2003, Experimental Neurology.

[11]  C. Broeckhoven,et al.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.

[12]  M. Albert,et al.  Results of a high-resolution genome screen of 437 Alzheimer's disease families. , 2003, Human molecular genetics.

[13]  Katrina A B Goddard,et al.  A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. , 2002, American journal of human genetics.

[14]  M. Owen,et al.  Full genome screen for Alzheimer disease: stage II analysis. , 2002, American journal of medical genetics.

[15]  Lars Bertram,et al.  New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.

[16]  K. Goddard,et al.  The amyloid precursor protein locus and very-late-onset Alzheimer disease. , 2001, American journal of human genetics.

[17]  C. Broeckhoven,et al.  Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. , 2000, Human molecular genetics.

[18]  M. Owen,et al.  Genetic variability at the amyloid-β precursor protein locus may contribute to the risk of late-onset Alzheimer's disease , 1999, Neuroscience Letters.

[19]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[20]  G. Benson,et al.  Tandem repeats finder: a program to analyze DNA sequences. , 1999, Nucleic acids research.

[21]  S. Sorbi,et al.  Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease , 1995, Annals of neurology.

[22]  S. Sorbi,et al.  ApoE genotype and familial Alzheimer's disease: a possible influence on age of onset in APP717 Val → Ile mutated families , 1995, Neuroscience Letters.

[23]  A. Hofman,et al.  Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease , 1994, Nature Genetics.

[24]  D. Pollen,et al.  Alzheimer's disease and possible gene interaction. , 1994, Science.

[25]  G. Schellenberg,et al.  Apolipoprotein E genotype and Alzheimer's disease , 1993, The Lancet.

[26]  Apolipoprotein E genotype and Alzheimer's disease. Alzheimer's Disease Collaborative Group. , 1993, Lancet.

[27]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[28]  G. Heinrich Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. , 1989, The New England journal of medicine.

[29]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[30]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[31]  J. Winn,et al.  Brain , 1878, The Lancet.

[32]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.